Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
20 sept. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
12 août 2021 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
09 juil. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference
06 juil. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
13 mai 2021 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I
12 avr. 2021 07h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Prioritize Next-Generation ETB Candidates
05 avr. 2021 07h00 HE
|
Molecular Templates, Inc.
Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued,...
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
18 mars 2021 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
26 févr. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering
18 févr. 2021 07h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...